1 stical significance at week 4 (key secondary
end point).
2 erated differentiation to the mineralization
end point.
3 end point, and 88 experienced the arrhythmic
end point.
4 used as either the primary or key secondary
end point.
5 an intermediate risk of reaching the primary
end point.
6 in similar outcomes for the primary efficacy
end point.
7 re observed in the components of the primary
end point.
8 ognitive Impairment (PCI) scale, our primary
end point.
9 [95% CI, 1.20-3.06]) risk of the arrhythmic
end point.
10 n and extended lifespan up to an eight-month
end point.
11 ) were independent predictors of the primary
end point.
12 ng-term mortality was a nonpowered coprimary
end point.
13 s performed in February 2019 for the primary
end point.
14 .97]) but not stroke or other cardiovascular
end points.
15 for examination of individual and composite
end points.
16 ocedure success were considered as secondary
end points.
17 ng sensitivity of the metals to different OP
end points.
18 outcomes but may be less suitable for other
end points.
19 [95% CI, 0.85-1.12]) or other cardiovascular
end points.
20 cute kidney injury at 30 days were secondary
end points.
21 have been shown to improve various oncologic
end points.
22 An independent committee adjudicated all
end points.
23 a and febrile neutropenia were key secondary
end points.
24 erformed using PFS and overall survival (OS)
end-points.
25 volutional neural networks were trained to 2
end points: (
1) sustained VT/VF or (2) mortality at 3 ye
26 Of 16 other prespecified secondary
end points,
10 showed no significant difference.
27 nd heparin monotherapy regarding the primary
end point (
180-day all-cause death, myocardial reinfarct
28 The primary study
end point,
3-year BPFS, was not met.
29 Of 38 prespecified secondary
end points,
34 showed no significant difference.
30 Of 5 prespecified secondary
end points,
4 are reported and 3 differed between groups
31 There were 47 primary
end points (
41 valve replacement, 1 death, and 5 hospita
32 Investigators identified 7529 prespecified
end points,
6793 of which were confirmed by the CEC: 98.
33 e assigned the Orsiro stent, met the primary
end point (
absolute risk difference 1.29% [upper limit o
34 apagliflozin reduced the risk of the primary
end point across each of these subgroups: hazard ratios
35 nscatheter heart valves (THVs) on individual
end points after transcatheter aortic valve replacement
36 ctions in risks for secondary kidney disease
end points (
albuminuria and a composite of serum creatin
37 used to derive the predictive value of each
end point,
along with combination approaches of multiple
38 In secondary
end point analyses, HR deficiency was identified in 69%
39 .45 [95% CI, 1.03-2.04]) risk of the primary
end point and 1.8-fold (hazard ratio, 1.82 [95% CI, 1.20
40 stituted primary safety and primary efficacy
end points and endothelial progenitor cell colony-formin
41 gn, convenient participation, and meaningful
end points and outcomes to improve patient recruitment a
42 Other efficacy
end points and safety were also evaluated.
43 CILP (primary
end point)
and event-free (EFS) and overall survival (OS
44 CR rates 97% versus 24% (P < .0001, primary
end point),
and blood MRD-free rates 100% versus 50% (P
45 low-up, 160 patients experienced the primary
end point,
and 88 experienced the arrhythmic end point.
46 ion and exclusion criteria, selected primary
end points,
and comparator populations to emulate those
47 uding noninferiority trial design, choice of
end points,
and prioritization of a patient's perspectiv
48 its effects on risks for death and ischemic
end points are still unclear.
49 ns of seizure activity and bi-stable seizure
end-points arise when stochastic noise is included.
50 nt at the time of retrieval (retrieval as an
end point)
as well as how emotion alters the way in whic
51 The primary efficacy
end point,
assessed with a Cox proportional-hazards mode
52 t (2.3% versus 1.4% for the primary efficacy
end point at 3 years, Gail-Simon qualitative P(interacti
53 The composite
end point at 30 days occurred in 45.1% versus 57.6% of p
54 ion individually or in combination for the 6
end points at 3 years.
55 Key secondary
end points at week 12 were the superiority of upadacitin
56 For secondary
end points,
bezafibrate reduced morning (P = .01 vs plac
57 ARTICIPANTS: Randomized, open-label, blinded
end-point clinical trial including 160 patients aged 60
58 The usefulness of adjudication by central
end point committees (CECs) is poorly assessed in heart
59 and-II Adaptive Behavior Scales, a secondary
end point comprising communication, socialization, and d
60 er event rates were assessed for the primary
end point,
consisting of a composite of all-cause death,
61 assigned to a group, 423 contributed primary
end point data.
62 ses included all participants with available
end-point data.
63 The primary
end point,
decreased Ki67, occured in 12% of TNBC.
64 ary end point was patient-oriented composite
end point,
defined as the composite of all-cause mortali
65 g), the individual components of the primary
end point,
definite stent thrombosis, or stroke.
66 The treatment effect on the composite renal
end point did not differ according to the baseline eGFR
67 None of the 8 secondary
end points differed significantly between the acetaminop
68 gitudinally to Identify Predictive Surrogate
End-points (
ECLIPSE) study.ResultsA total of 7143 COPDGe
69 Overall, 346 patients (25.1%) had a primary
end-point event (180 patients were intubated, of whom 66
70 A key secondary
end-point event occurred in 115 patients (4.2%) in the c
71 A primary
end-point event occurred in 187 patients (6.8%) in the c
72 ets, there were 107 composite cardiovascular
end point events (incidence rate per 1000 person-years,
73 of a possible benefit with respect to other
end-point events involving RSV-associated respiratory di
74 Two primary safety
end-point events occurred in the ablation group (Kaplan-
75 The rate of primary
end-point events was 5.6 events per 100 patient-years in
76 of events per 100 patient-years) of primary
end-point events was lower in the sotagliflozin group th
77 MRI-derived myocardial strain for a combined
end point (
events) of heart failure hospitalizations and
78 The 7 secondary
end points,
examined at multiple follow-ups, were point
79 The primary
end point for this analysis was the composite of (1) dea
80 The single
end point for this interim analysis was all-cause mortal
81 Primary and secondary
end points for CT and MRI guidance were compared by usin
82 This study thus identified earlier
end points for GA as potential therapeutic targets in cl
83 facilitate the development of biomarkers and
end points for pain.
84 d with fathead minnow embryos assessing five
end points (
hatching success, time to hatch, length, def
85 derable between-study heterogeneity for both
end points (
I2 > 90%).
86 were independent predictors of the composite
end point in adjusted analysis (LVH hazard ratio [HR], 3
87 aximize statistical power, we evaluated this
end point in the placebo group as compared with the comb
88 31 mm Hg had a 7x higher risk of the primary
end point in the reclassified group.
89 HRF and HRS may serve as structural
end points in clinical trials targeting AMD stages earli
90 severe glaucoma, many of which may serve as
end points in clinical trials, such as functional indepe
91 The assay (SELection
End points in Communities of bacTeria, or the SELECT met
92 esters, are significant as intermediates and
end points in fields such as organic, pharmaceutical, an
93 Secondary
end points included all-cause mortality and all major va
94 Secondary
end points included angiographic and safety outcomes.
95 Other secondary
end points included cartilage thickness on quantitative
96 Study
end points included changes in markers of systemic infla
97 Secondary
end points included death and appropriate shocks.
98 at 24 weeks (ORR(Wk24)); secondary efficacy
end points included duration of response (DOR), progress
99 Secondary
end points included duration of response, progression-fr
100 Functional phenotypic
end points included effects on beating parameters and in
101 Secondary and additional
end points included insulin use, the glycated hemoglobin
102 End points included LC50 values, and sublethal effects o
103 Key secondary
end points included major response rate (MRR), progressi
104 Key secondary
end points included overall (OS) and progression-free su
105 Secondary
end points included overall survival (OS), intracranial
106 Secondary
end points included overall survival and safety.
107 Secondary
end points included predisposing factors for treatment r
108 Secondary
end points included procedural complications within 30 d
109 Secondary
end points included progression-free survival (PFS), tox
110 Microbiome
end points included SER-287 engraftment (dose species de
111 Secondary
end points included the duration of response, progressio
112 Secondary
end points included the incidence of culprit vessels wit
113 Key
end points included the time-weighted average change in
114 Primary
end points included VTE recurrence, bleeding events, and
115 pared with docetaxel alone for any secondary
end point,
including survival in the elevated lactate de
116 across a variety of individual and composite
end points,
including all-cause mortality.
117 There were eight secondary
end points,
including the changes from baseline in the s
118 benefit with respect to all other secondary
end points,
including the time to first symptomatic skel
119 The primary composite functional
end point is clinical response at week 30 compared to ba
120 The primary
end point is pathologic complete response (pCR).
121 We compared the adjudication of prespecified
end points made by investigators and by the CEC.
122 et the criterion for noninferiority for this
end point (
margin, -10 percentage points).
123 criterion for noninferiority for the primary
end point (
margin, 6 percentage points).
124 Primary
end points:
mean decitabine systemic exposure (geometric
125 TOF), and single-cell sequencing enable only
end-point measurements and do not enable direct, quantit
126 lso greater in patients reaching the primary
end point (
median, 1208 [IQR, 0-4305] pg/mL versus media
127 Malignant ventricular arrhythmia
end points most commonly occurred in patients with sever
128 Regarding the primary
end point,
no intergroup differences were observed for t
129 Of the 6 prespecified secondary
end points,
none showed a statistically significant diff
130 The primary
end point occurred in 104 (4.0%) patients, myocardial in
131 0]; P=0.000001); the key secondary composite
end point occurred in 16.6% versus 12.1% (HR, 0.69 [95%
132 The primary composite
end point occurred in 24.7% of placebo-treated patients
133 The primary composite
end point occurred in 27.2% of CS and 26.4% of GA patien
134 The primary
end point occurred in 56% of women treated by the culpri
135 The primary
end point occurred in 785 patients (12.0%) treated with
136 The primary
end point occurred in 83 patients (10.1%) in the ticagre
137 -eGFR but not sCr-eGFR predicted the primary
end point:
odds ratio per 5 mL/(min.1.73 m(2)) decrease
138 four patients were evaluable for the primary
end point of a prostate-specific antigen (PSA)50 respons
139 agnetic resonance, with the 5-year composite
end point of all-cause death and hospitalization for hea
140 idogrel 600 mg regarding a composite primary
end point of all-cause death, any myocardial infarction,
141 ate, 80.0%), the rate of the trial's primary
end point of all-cause mortality occurred in 13.7% of pa
142 py in the reduction of the primary composite
end point of all-cause mortality or new Q-wave myocardia
143 discharged, we compared a primary composite
end point of cardiac arrest from ventricular tachycardia
144 The primary
end point of efficacy and safety was not different betwe
145 The primary
end point of interest was major adverse cardiac events,
146 nificantly reduce the primary cardiovascular
end point of major CVD events (composite of myocardial i
147 The incidence of the primary safety
end point of major peri-percutaneous coronary interventi
148 ociated with increased risk of the composite
end point of mortality, stroke, and rehospitalization at
149 zed phase II screening design with a primary
end point of overall survival (OS), using an alpha of .2
150 For the original coprimary
end point of the first occurrence of death from cardiova
151 I, 0.72 to 0.99); for the original coprimary
end point of the first occurrence of death from cardiova
152 ically significant difference in the primary
end point of the number of days alive and out of hospita
153 The primary
end point of this meta-analysis was progression-free sur
154 tion and after 2 weeks, as primary surrogate
end points of efficacy and safety, respectively.
155 Patients were assessed for primary
end points of engraftment and safety and for hematologic
156 End points of interest included in-hospital mortality, u
157 t Association class on presentation, and the
end points of mortality and heart failure admissions in
158 The BW, uterus weight, and histopathology
end points of the uteri were analyzed at postnatal (PND)
159 ificant differences in the risks of ischemic
end points or major bleeding were observed with midterm
160 ials with surrogate or intermediate clinical
end points or on non-inferiority trials, as well as new
161 It had 2 coprimary
end points:
OS and RFS.
162 y age interactions were seen for all primary
end points (
P-interaction<0.05 for each), such that the
163 The primary efficacy
end point,
percentage change in total plaque volume at 9
164 The primary
end point,
powered for noninferiority of the ACURATE neo
165 The key secondary
end point,
powered for superiority of the ACURATE neo bi
166 e clinical composite score (primary efficacy
end point),
quality of life, LV structural remodeling (
167 We also found that recovery
end points significantly varied intra-individually acros
168 eted the trial with ascertainment of primary
end point status.
169 The primary
end point,
stringent complete response (sCR) rate by the
170 and level III studies have variable primary
end points,
study design limitations, and only short-ter
171 llation (AF) in a way that reflects clinical
end points such as response to therapy.
172 rgins, using a study population and efficacy
end point that are sufficiently sensitive for detecting
173 (2) What are the
end points that are used to determine clinical utility?
174 reductions in the primary and key secondary
end points,
the US subgroup demonstrated particularly ro
175 Of the 31 prespecified secondary
end points,
there were statistically significant differe
176 suitable for use as an intermediate clinical
end point to substitute for OS to accelerate phase III (
177 xposure in vivo and in vitro, using relevant
end points to elucidate potential mechanisms of oral ars
178 We discuss the study populations and
end points used, extrapolation of indications, and the c
179 RTAVI trials, ascertainment of trial primary
end points using claims reproduced both the magnitude an
180 determined their risk of reaching a clinical
end point (
valve replacement for symptoms, hospitalizati
181 Both
end point variance and trajectory irregularities correla
182 The primary
end point was >=50% reduction of pruritus (VAS; intentio
183 Primary
end point was 12-month incidence of target vessel failur
184 s (linkage rate, 60.5%), the trial's primary
end point was 12.9% for TAVR and 13.1% for SAVR using tr
185 alpha/beta estimate for photographic
end point was 2.7 Gy (95% CI, 1.5 to 3.9 Gy), giving a 5
186 The primary
end point was 3-year BPFS.
187 The primary
end point was 3-year grade 2-3 breast induration assumin
188 The primary
end point was 30-day mortality; nonfatal myocardial infa
189 1 month and 1 year, the rate of the primary
end point was 7.0%.
190 In the prospective cohort, the primary
end point was a composite of in-hospital mortality, rena
191 The primary
end point was a composite of intubation or death in time
192 The primary safety
end point was a modification of the International Societ
193 The primary
end point was a sustained molecular response in the bone
194 The
end point was allergy status at age 4(+) years; samples
195 The primary
end point was an objective response (a complete or parti
196 The primary composite
end point was cardiovascular death, nonfatal myocardial
197 The primary
end point was change in 6-month MRI enhancement volume c
198 The primary
end point was change in log coronary artery calcium volu
199 The primary
end point was change in overall symptom severity over 14
200 The primary
end point was change in VO(2)peak (mL O(2).kg(-1).min(-1
201 The risk of patient-oriented composite
end point was comparable between the 2 groups (22.7% ver
202 The primary
end point was complete remission (CR) on induction.
203 The primary
end point was completion of the 2-hour dwell without sig
204 The primary
end point was concordant S aureus colonization by 90 day
205 The primary efficacy
end point was confirmed clinical response (CCR), 2 days
206 The primary
end point was death from any cause or disabling stroke.
207 The primary
end point was death from any cause within 30 days after
208 comfort or adverse events, and the secondary
end point was difference in sodium removal between DSR a
209 ); this decrease in composite cardiovascular
end point was driven by numeric decreases in the risk of
210 The key secondary
end point was durable overall response at day 56.
211 onse rate (ORR) at day 28; the key secondary
end point was duration of response (DOR) at 6 months.
212 Primary
end point was eGFR 2 years after transplantation.
213 The primary
end point was endogenous insulin production, as assessed
214 The primary
end point was event-free survival.
215 The primary
end point was first occurrence of severe morbidity (new
216 The primary
end point was hematologic response rate at 3 months.
217 The secondary efficacy
end point was hospitalization for RSV-associated lower r
218 The primary
end point was imaging-based progression-free survival in
219 The primary
end point was improvement from baseline of 15 or more ET
220 The primary
end point was improvement of 3-year DFS by oxaliplatin f
221 The clinical
end point was ischemic stroke.
222 The secondary
end point was left ventricular reverse remodeling (left
223 The primary
end point was major adverse cardiovascular and cerebrova
224 The primary
end point was median OS from diagnosis.
225 The primary
end point was met by 59 (35%) with combination therapy a
226 The primary
end point was met, with an sCR rate of 60% after 8 cycle
227 The primary
end point was met, with the ORR reaching 60.9% (95% CI,
228 The primary
end point was objective response rate (ORR) at 24 weeks
229 Primary
end point was objective response rate (ORR).
230 The primary
end point was objective response rate per RECIST v1.1.
231 The primary
end point was objective response rate.
232 The primary
end point was organ support-free days (days alive and fr
233 The primary
end point was overall response (complete response or par
234 The primary
end point was overall response rate (ORR) at day 28; the
235 The primary
end point was overall response rate (ORR) by RECIST vers
236 The primary
end point was overall response rate by consensus global
237 Primary
end point was overall survival (OS) evaluated using adju
238 The secondary
end point was patient-oriented composite end point, defi
239 The primary
end point was patient-reported quality of life using the
240 The primary
end point was percentage improvement in Eczema Area and
241 The primary
end point was progression-free survival (PFS) by blinded
242 The primary
end point was progression-free survival, with disease pr
243 The primary
end point was rate of stringent complete response (sCR)
244 The primary
end point was recurrence-free survival (RFS).
245 The primary
end point was RRs of arm A and arm B evaluated separatel
246 The primary
end point was safety.
247 The primary
end point was slope of GFR (DeltaGFR).
248 The primary
end point was standard deviation of lateral position (SD
249 The primary
end point was sustained testosterone suppression to cast
250 The primary effectiveness
end point was target-lesion primary patency, defined as
251 The primary
end point was the absolute change in plasma sodium conce
252 The primary
end point was the change from baseline in the total scor
253 The primary
end point was the change in gastrointestinal eosinophil
254 The primary
end point was the composite of device-related complicati
255 The primary
end point was the first documented recurrence of any atr
256 The primary
end point was the incidence of an unfavorable outcome, d
257 The secondary
end point was the incidence of bleeding defined as BARC
258 The primary
end point was the incidence of hypophosphatemia (serum p
259 The primary adverse event
end point was the incidence of treatment-emergent advers
260 The primary
end point was the invasive cancer detection rate.
261 The primary safety
end point was the number and severity of treatment-emerg
262 The primary
end point was the percent change from baseline in the LD
263 The primary
end point was the percentage of participants who had an
264 The primary
end point was the percentage of patients who had a reduc
265 The primary
end point was the percentage of patients with an objecti
266 The primary
end point was the proportion of patients achieving a com
267 The primary
end point was the total number of deaths from cardiovasc
268 The principal safety
end point was TIMI (Thrombolysis in Myocardial Infarctio
269 ng weeks 1 through 24, and the key secondary
end point was transfusion independence for 12 weeks or l
270 The primary
end point was transfusion independence for 8 weeks or lo
271 Primary
end point was visual acuity (VA) change from baseline to
272 ionship between treatments and falsification
end points was found, suggesting no evidence for substan
273 The pre-specified primary
end-point was relative change in airway subepithelial eo
274 Criteria for the primary
end point were met in 68.5% of 206 women in UF-1 and in
275 Primary
end points were (1) proportion of preterm infants who ac
276 Secondary
end points were 5-year locoregional control and disease-
277 End points were any progression of DR, onset of DR, and
278 Primary and secondary
end points were assessed in a hierarchic model to compar
279 Additional
end points were collected: HRQOL by FACT-BMT score at ba
280 y (eg, death and stroke) and secondary trial
end points were compared across treatment arms (eg, tran
281 All prespecified secondary
end points were consistently improved in the 300 IR grou
282 Eight primary
end points were developed to assess user comprehension o
283 The primary safety
end points were device related death or adverse events,
284 Primary and secondary
end points were disease-free survival (DFS) and overall
285 ed, overall survival and all other secondary
end points were evaluated.
286 The two primary
end points were freedom from recurrence of atrial fibril
287 The
end points were further used to generate reasonable inte
288 Secondary
end points were improvement in fibrosis (reduction of >=
289 incident HF after visit 5, and key secondary
end points were incident HF with preserved LVEF (HFpEF)
290 Primary
end points were IOP and change from baseline IOP through
291 Secondary
end points were locoregional control, local control with
292 Predefined
end points were major adverse cardiovascular events (MAC
293 The coprimary
end points were myocardial infarction and major bleeding
294 Secondary
end points were patient-reported outcomes, tolerability,
295 End points were progression-free survival (PFS), freedom
296 Additional
end points were progression-free survival (PFS), toxicit
297 Secondary efficacy
end points were similar in the two groups: ORR 16% (comp
298 Secondary
end points were treatment exposure and change in central
299 ee (EFS) and overall survival (OS; secondary
end points)
were compared with the COG A3973 historical
300 ugrel, each with alpha=0.016 for the primary
end point,
which was 30-minute IPA at light transmittanc